Navigation Links
Most prostate cancer specialists don't recommend active surveillance for low-risk patients
Date:6/16/2014

June 16, 2014 Specialists who treat prostate cancer agree that active surveillance is an effective optionyet most don't recommend it when appropriate for their own patients, according to a study in the July issue of Medical Care . The journal is published by Lippincott Williams & Wilkins , a part of Wolters Kluwer Health.

Rather, urologists are more likely to recommend surgery and radiation oncologists are more likely to recommend radiation therapythe treatments provided by their own specialties. "Given the growing concerns about the overtreatment of prostate cancer, our study has important policy implications about possible barriers to promoting active surveillance and specialty biases about optimal treatment regarding localized prostate cancer," comments Dr Simon P. Kim of Yale School of Medicine.

Most Prostate Specialists Rate Active Surveillance Effective

The researchers surveyed urologists and radiation oncologists regarding their views on options for "low-risk" prostate cancer. The study focused on perceptions of active surveillance as an initial approach.

Prostate cancer typically progresses slowlymost older men diagnosed with early-stage disease won't actually die of prostate cancer. For these low-risk cases, there's growing interest in active surveillance, in which patients are closely monitored for evidence of disease progression.

Active surveillance has emerged as an approach to avoid "overtreatment" of prostate cancer. In many cases, it can avoid surgery or radiation therapy that would entail a risk of complications and side effects without actually benefiting the patient.

Dr Kim and coauthors analyzed survey responses from 717 US urologists and radiation oncologists. Consistent with the research evidence, 72 percent of the specialists agreed that active surveillance is an effective alternative for men with low-risk prostate cancer. In addition, 80 percent agreed that active surveillance was underused in the United States.

But Don't Recommend It for Their Own Patients

"However, 71 percent of the physicians responded that their patients were not interested in active surveillance," the researchers write. The rate was over 80 percent for radiation oncologists, compared to 60 percent for urologists.

When asked what treatment they would recommend for a hypothetical 60-year-old man with low-risk prostate cancer, just 22 percent of the physicians said would endorse active surveillance. Instead, 45 percent would recommend surgery (radical prostatectomy) while 35 percent would recommend some form of radiation therapy.

In general, the recommendations split along specialty linesmost respondents recommended the treatment provided by their specialty. After adjustment for other factors, urologists were four times more likely to recommend surgery, compared to radiation oncologists. Urologists were also much less likely to recommend any form of radiation therapy.

Urologists were more than twice as likely to recommend active surveillance, compared to radiation oncologists. Doctors who worked in academic medical centers were also more likely to recommend active surveillance.

The survey adds to recent evidence that physicians view active surveillance as a "reasonable approach" to initial treatment in appropriate patients with low-risk prostate cancer. Both groups of specialists acknowledge the growing concern about overtreatment of prostate cancer.

However, "that hasn't consistently translated into their self-reported patterns of treatment recommendations," Dr Kim and colleagues write. "Our study suggests that there remain some key attitudinal barriers to active surveillance among prostate cancer specialists, especially considering radiation oncologists and urologists may view their treatment as superior."

The researchers discuss some options to better incorporate patient preferences into treatment decisionssuch as decision aids to provide men with evidence-based data on the advantages and disadvantages of treatment options. Coordinated, multidisciplinary care involving the patient's primary care providers as well as specialists may also provide a better balance between the risks and benefits of the different approaches. "By doing so, active surveillance may become a more acceptable disease management strategy for low-risk prostate cancer among newly diagnosed patients and specialists," Dr Kim and coauthors conclude.


'/>"/>
Contact: Connie Hughes
Connie.Hughes@wolterskluwer.com
646-674-6348
Wolters Kluwer Health
Source:Eurekalert

Related medicine news :

1. Guidelines address long-term needs of prostate cancer survivors
2. PSMA-based imaging traces even treatment-resistant prostate cancer
3. Gene therapy combined with IMRT found to reduce recurrence for select prostate cancer patients
4. Major advances in breast, prostate, colorectal cancer featured at ASCO Annual Meeting
5. New data shows ProMark accurately predicts aggressive prostate cancer, pathology outcomes
6. Radiation for prostate cancer linked to secondary cancers, study finds
7. Study affirms value of epigenetic test for markers of prostate cancer
8. Study shows image fusion-guided biopsy improves accuracy of prostate cancer diagnosis
9. Phase III clinical trial shows image fusion-guided biopsy significantly improves accuracy of prostate
10. Prolaris® test predicts mortality risk in prostate cancer biopsy study
11. Robot-assisted prostate cancer surgery as safe but more expensive as open surgery in older men
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals plc ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, ... of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ... (Eastern Daylight Time). As previously announced on ... a definitive merger agreement under which Jazz Pharmaceuticals has ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
Breaking Medicine Technology: